GE HealthCare Technologies enters the back half of August in an awkward spot — up 15% over the past month on the back of a strong Q2 print, yet shorts have been methodically adding to positions even as the stock consolidates near $72.63.
The short interest rebuild is the most interesting dynamic right now. Bears added roughly 24% to their position over the past month, bringing short interest to 4.2% of the free float — not an alarming level, but the direction is deliberate. The week-on-week uptick of about 1.5% continues a steady accumulation that began in mid-July, when SI was closer to 3.4% of float. That mid-July period also coincided with a spike in the lending market: availability tightened sharply to a 52-week low of around 949% on July 24 — meaning the pool of shares available to borrow dropped to its smallest relative to existing short positions all year — before easing back to a much looser 1,565% now. The normalization of availability suggests the July squeeze in the borrow market has cleared, making it cheaper and easier to add new short positions. Cost to borrow backs that up: at 0.42%, it ticked up roughly 28% on the week but remains well within "easy borrow" territory. The borrow market is loose; shorts are not being squeezed.
Options positioning adds a mild cautionary note, though nothing dramatic. The put/call ratio edged to 0.59, slightly above its 20-day average of 0.56 — a z-score of 0.74, which is a gentle lean toward protection rather than a clear hedge signal. Against that backdrop, the options market is not sounding alarms; it is simply running a little more defensively than its recent norm. The stock's 52-week PCR high of 2.22 puts current readings firmly in neutral territory.
The Street tilts constructive but conditionally so. Following the Q2 beat — the stock jumped over 9% on July 29 and held nearly all of those gains over the subsequent five days — bulls raised targets while largely keeping their powder dry on ratings. Wells Fargo and Evercore ISI both lifted targets into the $84–85 range on positive ratings. UBS and Citi moved targets higher too, to $73 and $75 respectively, but stayed at Neutral — a pattern that reads as "better than feared, but fully valued here." BTIG reiterated its Buy and $79 target as recently as this week. The consensus mean target is $82.50, implying roughly 14% upside from current levels, though the stock is now trading through several of the neutral targets, which narrows the incentive for fresh buying from that cohort. One data point to treat carefully: a $14 target attributed to Hovde Group from mid-July appears inconsistent with the rest of the analyst universe and may reflect a different share class or coverage initiation issue — it has been excluded from the above framing.
The factor picture tells a steady-state story. The dividend score ranks in the 93rd percentile — a genuine standout. EPS surprise ranks 77th percentile, consistent with a company that has beaten estimates reliably. The short score of 39.9 is mid-range and has barely moved over the past two weeks, suggesting the bears are rebuilding positions gradually rather than aggressively loading up. The days-to-cover rank at the 29th percentile implies the short position could be unwound quickly if needed, which limits squeeze risk. One institutional note worth flagging: Dodge & Cox holds over 10% of shares and added more than 16 million shares in the most recent reported period through July 31 — a sizable conviction add that sits on the other side of the short rebuild.
The next scheduled earnings date is October 30. After the last two prints produced single-day moves of 9% and 18% respectively — both positive — that date will attract attention from both sides of the trade. Between now and then, the key question is whether the short rebuild stalls as the stock digests its post-earnings gains, or whether bears press further as the bull case gets priced in near the top of the neutral analyst target cluster.
See the live data behind this article on ORTEX.
Open GEHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
